Wilmington, United States
ERGO, a biotech startup founded in 2020, is pioneering the field of complex animal protein production through plant cell precision fermentation. Rooted in the belief that plant cells are highly sophisticated systems, ERGO has developed a platform to execute multiple genetic modifications to produce millions of plant cells, akin to mass-producing computer processors. This novel approach represents a breakthrough in plant-based biotechnology.
ERGO focuses on creating clones that express mammalian proteins, advancing both the nutritional and sensory attributes of plant-based meats and cheeses. Their flagship products include bovine myoglobin for meats and bovine caseins for cheeses, aiming to elevate the organoleptic experience of plant-based foods.
Headquartered in the United States, the company recently secured a €1.50M Seed Round investment on 20 September 2023 from leading investors including Pascual Innoventures, Mylkcubator, and the Global Agri-Food Advancement Partnership. As ERGO positions itself at the confluence of Biopharma, Biotechnology, Food and Beverage, and Life Sciences, it stands poised for catalytic growth and impact.
